CA3174223A1 - Co-administration of mirdametinib and lifirafenib for use in treating cancers - Google Patents
Co-administration of mirdametinib and lifirafenib for use in treating cancers Download PDFInfo
- Publication number
- CA3174223A1 CA3174223A1 CA3174223A CA3174223A CA3174223A1 CA 3174223 A1 CA3174223 A1 CA 3174223A1 CA 3174223 A CA3174223 A CA 3174223A CA 3174223 A CA3174223 A CA 3174223A CA 3174223 A1 CA3174223 A1 CA 3174223A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- administered
- per day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063005153P | 2020-04-03 | 2020-04-03 | |
| US63/005,153 | 2020-04-03 | ||
| PCT/US2021/025551 WO2021202981A1 (en) | 2020-04-03 | 2021-04-02 | Co-administration of mirdametinib and lifirafenib for use in treating cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3174223A1 true CA3174223A1 (en) | 2021-10-07 |
Family
ID=75674969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3174223A Pending CA3174223A1 (en) | 2020-04-03 | 2021-04-02 | Co-administration of mirdametinib and lifirafenib for use in treating cancers |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US12667560B2 (enExample) |
| EP (1) | EP4125842B1 (enExample) |
| JP (2) | JP7748386B2 (enExample) |
| KR (1) | KR20230048476A (enExample) |
| CN (1) | CN116194095B (enExample) |
| AU (1) | AU2021246141A1 (enExample) |
| BR (1) | BR112022019914A2 (enExample) |
| CA (1) | CA3174223A1 (enExample) |
| CL (1) | CL2022002682A1 (enExample) |
| CO (1) | CO2022015891A2 (enExample) |
| DK (1) | DK4125842T3 (enExample) |
| ES (1) | ES2985012T3 (enExample) |
| FI (1) | FI4125842T3 (enExample) |
| HU (1) | HUE067894T2 (enExample) |
| IL (1) | IL296878A (enExample) |
| MX (1) | MX2022012351A (enExample) |
| PE (1) | PE20231211A1 (enExample) |
| PL (1) | PL4125842T3 (enExample) |
| PT (1) | PT4125842T (enExample) |
| TW (1) | TWI893097B (enExample) |
| WO (1) | WO2021202981A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL4125842T3 (pl) | 2020-04-03 | 2024-10-14 | Beigene, Ltd. | Równoczesne podawanie mirdametynibu i lifirafenibu do stosowania w leczeniu nowotworów |
| US20230293464A1 (en) * | 2022-03-17 | 2023-09-21 | SpringWorks Therapeutics Inc. | Treatment of pancreatic ductal adenocarcinoma with mirdametinib |
| MX2024011403A (es) * | 2022-03-17 | 2024-09-23 | Springworks Therapeutics Inc | Tratamiento con mirdametinib. |
| WO2023209611A1 (en) * | 2022-04-26 | 2023-11-02 | Beigene Switzerland Gmbh | Methods of treating cancer with a b-raf inhibitor, in particular lifirafenib |
| EP4601631A4 (en) * | 2022-10-14 | 2026-04-08 | Springworks Therapeutics Inc | COMBINATION INTENDED FOR USE IN CANCER TREATMENT |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004501190A (ja) | 2000-06-23 | 2004-01-15 | テバ ファーマシューティカル インダストリーズ リミティド | 治療薬の胃部保留および制御された放出のための急速膨張する組成物とその組成物を含む剤形 |
| AU7349801A (en) | 2000-07-19 | 2002-01-30 | Warner Lambert Co | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| EP1562601A1 (en) | 2002-11-15 | 2005-08-17 | Warner-Lambert Company LLC | Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer |
| KR101013932B1 (ko) | 2003-10-21 | 2011-02-14 | 워너-램버트 캄파니 엘엘씨 | Ｎ-[(ｒ)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도페닐아미노)-벤자미드 다형체 형태 |
| WO2006061712A2 (en) | 2004-12-10 | 2006-06-15 | Pfizer Inc. | Use of mek inhibitors in treating abnormal cell growth |
| WO2006134469A1 (en) | 2005-06-14 | 2006-12-21 | Warner-Lambert Company Llc | Methods of preparing mek inhibitor |
| WO2007042885A2 (en) | 2005-10-07 | 2007-04-19 | Pfizer Products Inc. | Therapeutic combination comprising methotrexate and a specified inhibitor of mek1 and mek2 |
| TR201815685T4 (tr) | 2011-04-01 | 2018-11-21 | Genentech Inc | Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları. |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| AU2016248376B2 (en) | 2015-04-15 | 2020-10-08 | Beone Medicines I Gmbh | Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore |
| KR102811888B1 (ko) | 2017-09-08 | 2025-05-27 | 에프. 호프만-라 로슈 아게 | 암의 진단 및 치료 방법 |
| WO2019113345A1 (en) | 2017-12-06 | 2019-06-13 | Spyro Mousses | Combination of cancer therapeutics for treatment of cancer and hyperproliferative diseases |
| EP3560516A1 (en) | 2018-04-27 | 2019-10-30 | Bergen Teknologioverforing AS | Combination therapy including beta-sitosterol in combination with at least one of a braf inhibitor, a mek inhibitor or an erk inhibitor and methods and use thereof |
| US12208099B2 (en) | 2018-09-10 | 2025-01-28 | Mirati Therapeutics, Inc. | Combination therapies |
| PL4125842T3 (pl) | 2020-04-03 | 2024-10-14 | Beigene, Ltd. | Równoczesne podawanie mirdametynibu i lifirafenibu do stosowania w leczeniu nowotworów |
| US11066358B1 (en) | 2021-02-17 | 2021-07-20 | Warner-Lambert Company Llc | Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
| US11571402B2 (en) | 2021-02-17 | 2023-02-07 | Springworks Therapeutics, Inc. | Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
| US11084780B1 (en) | 2021-02-17 | 2021-08-10 | Springworks Therapeutics, Inc. | Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
| MX2024011403A (es) | 2022-03-17 | 2024-09-23 | Springworks Therapeutics Inc | Tratamiento con mirdametinib. |
| PE20242177A1 (es) | 2022-03-17 | 2024-11-07 | St Jude Childrens Res Hospital Inc | Tratamiento del glioma de bajo grado con mirdametinib |
-
2021
- 2021-04-02 PL PL21721706.6T patent/PL4125842T3/pl unknown
- 2021-04-02 ES ES21721706T patent/ES2985012T3/es active Active
- 2021-04-02 TW TW110112271A patent/TWI893097B/zh active
- 2021-04-02 CA CA3174223A patent/CA3174223A1/en active Pending
- 2021-04-02 FI FIEP21721706.6T patent/FI4125842T3/fi active
- 2021-04-02 JP JP2022560245A patent/JP7748386B2/ja active Active
- 2021-04-02 PT PT217217066T patent/PT4125842T/pt unknown
- 2021-04-02 DK DK21721706.6T patent/DK4125842T3/da active
- 2021-04-02 HU HUE21721706A patent/HUE067894T2/hu unknown
- 2021-04-02 PE PE2022002181A patent/PE20231211A1/es unknown
- 2021-04-02 AU AU2021246141A patent/AU2021246141A1/en active Pending
- 2021-04-02 KR KR1020227038490A patent/KR20230048476A/ko active Pending
- 2021-04-02 IL IL296878A patent/IL296878A/en unknown
- 2021-04-02 WO PCT/US2021/025551 patent/WO2021202981A1/en not_active Ceased
- 2021-04-02 US US17/995,002 patent/US12667560B2/en active Active
- 2021-04-02 EP EP21721706.6A patent/EP4125842B1/en active Active
- 2021-04-02 BR BR112022019914A patent/BR112022019914A2/pt unknown
- 2021-04-02 CN CN202180036587.XA patent/CN116194095B/zh active Active
- 2021-04-02 MX MX2022012351A patent/MX2022012351A/es unknown
-
2022
- 2022-09-30 CL CL2022002682A patent/CL2022002682A1/es unknown
- 2022-11-03 CO CONC2022/0015891A patent/CO2022015891A2/es unknown
-
2025
- 2025-06-18 JP JP2025102055A patent/JP2025120501A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230128315A1 (en) | 2023-04-27 |
| IL296878A (en) | 2022-12-01 |
| HUE067894T2 (hu) | 2024-11-28 |
| ES2985012T3 (es) | 2024-11-04 |
| CN116194095A (zh) | 2023-05-30 |
| PL4125842T3 (pl) | 2024-10-14 |
| EP4125842A1 (en) | 2023-02-08 |
| CO2022015891A2 (es) | 2023-05-08 |
| JP2023521036A (ja) | 2023-05-23 |
| EP4125842B1 (en) | 2024-06-05 |
| TWI893097B (zh) | 2025-08-11 |
| PT4125842T (pt) | 2024-08-06 |
| US12667560B2 (en) | 2026-06-30 |
| JP7748386B2 (ja) | 2025-10-02 |
| PE20231211A1 (es) | 2023-08-17 |
| MX2022012351A (es) | 2023-03-13 |
| DK4125842T3 (da) | 2024-07-22 |
| FI4125842T3 (fi) | 2024-08-06 |
| JP2025120501A (ja) | 2025-08-15 |
| CL2022002682A1 (es) | 2023-06-16 |
| KR20230048476A (ko) | 2023-04-11 |
| CN116194095B (zh) | 2024-09-13 |
| AU2021246141A1 (en) | 2022-12-01 |
| TW202207910A (zh) | 2022-03-01 |
| BR112022019914A2 (pt) | 2022-12-13 |
| WO2021202981A1 (en) | 2021-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7748386B2 (ja) | がんの治療で使用するためのミルダメチニブ及びリフィラフェニブの同時投与 | |
| ES2378255T3 (es) | Titulación de tapentadol | |
| ZA202201465B (en) | Long-lasting formulation containing rivastigmine, and method for preparing same | |
| CN101622013A (zh) | 包含丁丙诺啡和纳洛酮的改善的药用组合物 | |
| WO2019006050A1 (en) | NK-1 ANTAGONIST COMPOSITIONS AND METHODS FOR USE IN TREATING DEPRESSION | |
| JP2006511538A (ja) | 非ヌクレオシド系逆転写酵素阻害剤（ｎｎｒｔｉ）とプロテアーゼ阻害剤などのシトクロムｐ４５０の阻害剤とを含む組み合わせの使用 | |
| CN110719778A (zh) | 用于治疗抑郁的组合物和方法 | |
| EP3982970A1 (en) | New treatment of sma | |
| CN101754760A (zh) | 用以改善伴随着前列腺肥大的下尿路症状的药物组合物 | |
| Moyao-García et al. | A pilot study of nalbuphine versus tramadol administered through continuous intravenous infusion for postoperative pain control in children | |
| JP3792251B2 (ja) | 手術後の悪心および嘔吐の治療のためのグラニセトロンの使用 | |
| EP4117638B1 (en) | Controlled release formulations comprising drotaverine or salt thereof | |
| RU2671575C2 (ru) | Применение солифенацина и стимуляторов слюноотделения в лечении гиперактивного мочевого пузыря | |
| JP2022520276A (ja) | ベンズイミダゾール誘導体化合物を含む医薬組成物 | |
| AU716972B2 (en) | Method for treating bipolar disorder | |
| US12303503B1 (en) | Use of dextromethorphan in combination with CYP2D6 and CYP3A4 enzyme inhibitors for the treatment of pain | |
| JP6042886B2 (ja) | 早漏症治療用の薬学組成物 | |
| HK40116800A (en) | Compositions and method for treating depression | |
| CN116635034A (zh) | 用于治疗人低胆碱能障碍的药物组合 | |
| Podolsky et al. | Randomized clinical trial of the safety and efficacy of oxymorphone extended release for degenerative disc disease in opioid-naive patients | |
| Rauck et al. | Conversion and titration from oxycodone to oxymorphone extended release in patients with chronic low back pain | |
| CA2586231A1 (en) | Method for treating hiv infection through co-administration of tipranavir and uk-427, 857 | |
| CN106413698A (zh) | 耳鸣患者的治疗用药剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241104 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250328 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250328 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250402 |
|
| D16 | Fast track examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D16-D108 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ADVANCED EXAMINATION REQUESTED - PPH Effective date: 20250402 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250402 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250402 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250403 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250407 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250407 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250407 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250409 |
|
| D17 | Fast track examination accepted |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D17-D112 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ADVANCED EXAMINATION DETERMINED COMPLIANT - PPH Effective date: 20250416 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250430 |
|
| D17 | Fast track examination accepted |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D17-D161 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PPH RETAINED AFTER REVIEW Effective date: 20250505 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250512 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250516 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250912 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251222 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251222 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251222 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260306 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260327 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260327 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260703 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260706 |